 Analysis: A total sample size of 333 patients 111 per group will be required to detect an improvement of at least 3.1 months in progression free survival from 5.5 to 8.6 months using a 2-tailed comparison, 2.5 level of significance, 3-year accrual and 1-year follow-up. The 12-month survival rate for patients on capecitabine alone is 50. A sample size of 111 per arm will have 80 power to detect an increase of 17 in the 1-year rate from 50 to 67 based on a significance level of 2.5, 3-year accrual and 1-year follow-up. For both endpoints PFS and survival the difference between capecitabine alone and the regimen containing MMC is expected to be greater in the order of 4.5 months which will yield 80 power to detect the difference in PFS. 